METABOLOMIC INSIGHTS: LC-MS PROFILING OF HUMAN PLACENTAL TISSUE FROM SSRI-TREATED PREGNANCIES

Anna Itkonen MSc. [1]:, Olli Kärkkäinen DSc.[1]:, Marko Lehtonen PhD[1]:, Heidi Sahlman PhD[1]:, Leea Keski-Nisula MD, PhD[2,3]:, Jaana Rysä PhD[1]

[1] School of Pharmacy, University of Eastern Finland, Finland

[2] Institute of Clinical Medicine, School of Medicine, University of Eastern Finland, Finland

[3] Department of Obstetrics and Gynecology, Kuopio University Hospital, Finland

Corresponding author: Prof. Jaana Rysä, Yliopistonrinne 3, School of Pharmacy, University of Eastern Finland, 70210 Kuopio, Finland; jaana.rysa@uef.fi. ORCID: 0000-0003-2205-6323

Abstract

Introduction: Antenatal depression, a common pregnancy complication, poses significant risks if untreated. Consequently, pregnant mothers are prescribed selective serotonin reuptake inhibitors (SSRIs).

Methods: We performed a comprehensive determination of the placental metabolome by nontargeted liquid chromatography-mass spectrometry (LC-MS) metabolomics approach to determine whether SSRIs alter placental metabolic functions. A total of 48 placental samples from individuals using SSRI medication throughout the pregnancy (n = 24) and non-depressive controls without antidepressant medication (n = 24) were included.

Results: We found significant alterations in glutathione, amino acid, and lipid metabolism, potentially indicating a response to changes in placental redox homeostasis and energy metabolism. Furthermore, four of the altered metabolites were positively associated with the 5-minute Apgar score in SSRI-treated pregnancies, indicating that higher metabolite levels may correlate with better birth outcomes.

Discussion: Given the limited research on placental metabolomics, our exploratory study provides new insights into SSRI-induced changes in the placenta.

Key words: antidepressant, depression, metabolism, metabolome, non-targeted metabolomics

Introduction

Depression is a common complication during pregnancy, with untreated antenatal depression posing significant risks to both the mother and the developing fetus [1]. Emerging evidence from both rodent and human studies suggests that the placenta can transmit maternal depression and stress to the fetus, potentially resulting long-term mood disorders in offspring [2]. Thus, selective serotonin reuptake inhibitors (SSRIs) are frequently prescribed during pregnancy.

SSRIs exert their effects by inhibiting serotonin (5-HT) reuptake through serotonin transporters (SERT), increasing extracellular 5-HT levels in the central nervous system and peripheral tissues, including the placenta [3]. In the placenta, SERT is expressed on the maternal-facing brush border membranes of the trophoblast cells [4]. Furthermore, placenta exhibits a 5-HT system, which is crucial for pregnancy progression and early embryonic development, regulating cell division, morphogenesis, and neuronal plasticity and supporting placental blood flow and fetal brain development [5–7]. Thus, the placenta is vulnerable to disruptions in placental 5-HT homeostasis.

By inhibiting placental SERT, SSRIs may interfere with 5-HT signaling, critical for placental function and the development of the fetal central nervous system and other organs [3,6]. SSRI usage during pregnancy is associated with increased risks of major congenital malformations, congenital heart defects, preterm birth, neonatal adaptation symptoms, and persistent pulmonary hypertension of the newborn, particularly with paroxetine and fluoxetine [8].

Reported by us and others, SSRIs have the potential to alter placental functions critical for fetal development such as gene expression, and the function of transporters, enzymes, and growth factors [3,9–16]. Theoretically, these impairments could be reflected in the placental metabolome. Earlier metabolomic studies link SSRIs with circulating metabolic disturbances. In non-pregnant populations, SSRI use has been linked to changes in glucose metabolism, lipid profiles, and weight gain [17,18]. These systemic metabolic changes suggest that SSRIs may disrupt not only neural signaling but also broader physiological pathways that are essential for cellular homeostasis.

Despite the observed effects of SSRIs on the circulating metabolome and placental function, there is a notable lack of data assessing how SSRIs affect the placental metabolome. Since the placenta acts as the key intermediary between the mother and the developing fetus, understanding its metabolic response to SSRI exposure is critical for elucidating potential risks posed to the fetus.

To address this gap in knowledge, we conducted a comprehensive metabolic profiling of placental tissues from SSRI-treated pregnancies using a nontargeted liquid chromatography-mass spectrometry (LC-MS) approach. LC-MS offers the broadest scope of metabolome analysis among available methods, capable of elucidating metabolic pathway regulation and diverse exposures [19].

Furthermore, metabolomics offers a detailed snapshot of biochemical and physiological states, aiding in identifying toxicological mechanisms and stress responses [20]. Our study aims to characterize the differences in the placental metabolome between SSRI-treated pregnancies and control pregnancies without antidepressant treatment to better understand the placental responses of SSRIs. Additionally, we sought to explore the association between placental metabolic profiles and neonatal and maternal outcomes, such as birth weight, Apgar scores, and placental weight.

Materials & methods

Clinical subjects and sample collection

A total of 48 placentas from individuals using SSRI medication throughout the pregnancy (n = 24) and non-depressive control individuals without antidepressant medication (n = 24) were included in the study. The placental sample collection is standardized within the Kuopio Birth Cohort (KuBiCo) [21]. The samples originate from pregnant individuals donating placenta after giving birth at Kuopio University Hospital (KUH) during the years 2013-2015. The samples were collected by midwives in the delivery room. Twenty pieces from the basal plate were collected after delivery, divided into four tubes, frozen in liquid nitrogen, and stored at -80°C. The tissue collected did not include the chorionic plate but consisted of tissue from the basal plate and villi.

All participants in the KuBiCo study provided a written informed consent. The study was conducted in accordance with the guidelines outlined in the Declaration of Helsinki. Ethical approval was obtained from the Research Ethics Committee of the Hospital District of Central Finland in Jyväskylä, Finland on November 15, 2011 (18U/2011). The study was conducted in accordance with the Strengthening the reporting of observational studies in epidemiology (STROBE) guidelines [22].

Data on SSRI use and the diagnosis of gestational diabetes (GDM) (ICD-10 code O24.4) and preeclampsia (ICD-10 code O14-O15) were collected from the KUH Birth Register, which contains demographic and clinical information about the study participants. The Birth register also included a self-reporting section to report the use of over-the-counter and prescription drugs, as well as smoking during pregnancy. The smoking status of participants was confirmed by measuring serum cotinine level from blood samples collected at birth using a previously described method [11].

Sample preparation

Prior to LC-MS analysis, placental samples were subjected to cryogenic grinding to homogenize the tissue. Approximately 1-2 grams of the deep frozen (-80°C) tissue was grinded with QIAGEN® TissueLyser II for one minute (Frequency 30.0 1/s). Powdered frozen tissue was stored in -80°C until the metabolomics analysis.

Nontargeted LC-MS profiling

The samples were analyzed with two LC-MS methods [23]. Prior to analysis, 80% methanol was added to the powdered placental tissue at a ratio of 1:3 (e.g.,100 mg of sample + 300 µl of 80% methanol). The samples were carefully mixed and centrifuged for 10 minutes at +4°C and 16100 rcf. The samples were then diluted 1:1 with 80% methanol (200 µl of sample + 200 µl of 80% methanol). The diluted samples were filtered using a syringe filter (15161499, PTFE syringe filter 13mm, 0.2 µm) into a high-performance liquid chromatography vial insert. For more hydrophilic compounds, hydrophilic interaction chromatographic technique (HILIC) was used with both positive and negative electrospray ionization. For more lipophilic compounds, we utilized reversed phase (RP) chromatography and collected data with both electrospray ionization polarities. Both chromatographic techniques were connected to high-accuracy and high-resolution mass spectrometer. A pooled sample from all placental samples was injected at the beginning and end of the analysis to equilibrate the analytical platform and then after every 12 samples throughout the analysis for quality control.

We employed the open-source software MS-DIAL version 4.9.221218 for peak picking, peak alignment, and metabolite identification [24]. Consequently, we conducted preprocessing of the metabolomics data employing "notame" R-package (version 0.3) [25]. Key preprocessing steps involved drift correction, flagging low-quality features, and missing value imputation. The data quality is monitored at each step of the preprocessing according to the protocol detailed in Klåvus et al. (2020) [25].

Statistical analysis

For the clinical characteristics, continuous variables were analyzed with Welch's t-test or Wilcoxon rank-sum test for parametric and nonparametric variables, respectively. Categorical variables were analyzed with Fisher's exact test.

For feature-wise analysis of the metabolomics data, we employed Welch's t-test to calculate p-values for each molecular feature independently, employing FDR-correction to address the issue of multiple testing. Q-values (FDR corrected p-values) < 0.05 were considered statistically significant, whereas molecular features with p-value < 0.05 but q-value > 0.05 were considered trends. Moreover, Cohen's d effect sizes were computed to measure the magnitude of differences between the study groups. A positive Cohen's d value indicates that the metabolite abundance was increased in SSRI-cases and a negative value indicates a decrease in SSRI-cases compared to controls. For multivariate analysis of the metabolomics data, we used principal component analysis (PCA), and partial least sum of squares discriminant analysis (PLS-DA) calculated with SIMCA (version 17, Sartorius Stedim Data Analytics AB).

To account for potential confounding factors, we conducted a linear regression analysis on metabolites with biological relevance that exhibited statistically significant differences between the SSRI-cases and controls. The initial model (model 1) included merely the group (SSRI vs. control). The selected covariates for modeling possible influence of lifestyle included BMI, cotinine, and co-medication (model 2) and for modeling possible influence of pregnancy we included mode of delivery, fetal sex, preeclampsia, and GDM (model 3) due to their known influences on the maternal metabolome [26–29]. Regression analyses were performed in R (version 4.3.3). Finally, we investigated the associations between the significantly altered metabolites and placental weight, infants' birth weight and Apgar scores with Spearman's correlation coefficients.

Metabolite identification

Following Welch's t-test, molecular features displaying a false discovery rate (FDR)-corrected q-value below 0.05 underwent metabolite identification, while those with non-corrected p-values below 0.05 were also analyzed for trends. The identified metabolites were categorized into identification levels 1 and 2 according to the community standards [30].

Results

Clinical data

The clinical characteristics of the cohort exhibited a uniform distribution, although SSRI-cases had significantly higher placental weights (Table 1). The most often used SSRI was citalopram, accounting for 50% (n = 12) for the cases, followed by escitalopram (25.0%, n = 6), sertraline (20.8%, n = 5), and fluoxetine (4.2%, n = 1) (Supplementary Table 1). Depression was the most frequent indication for the SSRI treatment (62.5%, n = 15), followed by panic disorder (20.8%, n = 5), anxiety (8.3%, n = 2), bipolar disorder (4.2%, n = 1) and muscle spasm (4.2%, n = 1).

Table 1 Clinical characteristics of study participants with selective serotonin reuptake inhibitor users (SSRI) (n = 24) and controls without antidepressant medication (n = 24)

Variable	Control	SSRI	p-value*
	n = 24	n = 24	
Age, years	29.0 ± 4.2	30.8 ± 4.8	0.179
Parity	0.87 ± 1.0	1.12 ± 1.0	0.343
Self-reported smoking			
Not smoking	13 (56.5)	19 (86.4)	
Quit smoking before pregnancy	3 (13.0)	0 (0.0)	0.994[a]
Smoked during pregnancy	7 (30.4)	3 (13.6)	0.115[a]
Cotinine, ng/ml[1]	3.92 ± 16.3	4.89 ± 13.7	0.177
Co-medication	9 (37.5)	15 (62.5)	0.083
BMI at the beginning of pregnancy, kg/m^2	24.4 ± 4.1	28.2 ± 8.7	0.063
<25	15 (62.5)	10 (41.7)	
25-30	7 (29.2)	6 (25.0)	
>30	2 (8.3)	8 (33.3)	
BMI before delivery, kg/m^2	29.1 ± 4.3	32.7 ± 8.0	0.056
<25	4 (16.7)	2 (8.3)	
25-30	9 (37.5)	9 (37.5)	
> 30	11 (45.8)	13 (54.2)	
Number of fetuses	1.0 ± 0.0	1.0 ± 0.2	
Gestational diabetes mellitus[2]	4 (16.7)	6 (25.0)	0.725
Preeclampsia[2]	1 (3.4)	2 (4.0)	1.000
Obstetric and early neonatal characteristics			
Gestational weeks at delivery			1.000
Term ≥ 37	23 (95.8)	23 (95.8)	
Moderately preterm 32-36	1 (4.2)	1 (4.2)	
Mode of delivery[3]			0.187
Vaginal	21 (95.5)	18 (78.3)	
Caesarean section	1 (4.5)	5 (21.7)	
Placental weight, grams[2]	548.9 ± 86.1	646.7 ± 124.7	**0.040**
Birth weight, grams	3364 ± 455	3526 ± 561	0.592
Placental weight / Birth weight -ratio	15.71 (0.04)	17.83 (0.06)	0.154
Infant sex (n male)	10 (41.7)	16 (66.7)	0.147
Apgar scores at 1min	8.79 ± 0.7	8.33 ± 1.8	0.635
Apgar scores at 5min	9.16 ± 0.5	8.71 ± 1.1	0.113

Data is shown as mean ± SD or n (%).* Welch's t-test or Wilcoxon rank-sum test for continuous variables, Fisher's exact test for categorical variables. Logistic regression [a] the values were correlated to" not smoking", [1] n = 47, [2] n = 46, [3] n = 45, BMI; Body mass index, Co-medication; reported use of other medication than selective serotonin reuptake inhibitors

Metabolite profiling

In the metabolomics analysis, we measured a total of 18162 molecular features (Supplementary Table 2), of which 3086 features had raw p-values below 0.05 and 862 features had FDR-corrected q-values below 0.05 (Supplementary Table 3 shows features with MS/MS data). Principal component analysis (PCA) showed some separation between the SSRI-treated cases and controls based on the first two principal components (Figure 1A). The results of the PLS-DA model with two components (R2Y(cum)=0.96, Q2(cum)=0.62) were in line with the results from the feature-wise analyses (Figure 1B). The identified metabolites with p-value below 0.05 are depicted in Figure 1C.



Figure 1 Overview of the metabolite profiling results from the placental samples. Panel A, principal component analysis (PCA) score plot showing first two components explaining 9% and 8% of the variation in the data are shown. The second component shows some separation of the SSRI -cases and controls. Panel B, partial least sum of squares discriminant analysis (PLS-DA) score plot of metabolomic profiles of SSRI-cases compared to controls (2 components, R2Y(cum)=0.96, Q2(cum)=0.62). Panel C shows all the identified metabolites with p-value below 0.05 and Cohen's d effects sizes. A positive Cohen's d value indicates that the metabolite abundance was increased in SSRI-cases, and a negative value indicates a decrease in SSRI-cases compared to controls. Metabolites with q-value below 0.05 and VIP-values (from PLS-DA) above 1.5 are marked with asterisk (*). GSSG, oxidized glutathione; NADH, nicotinamide adenine dinucleotide; PC, phosphatidylcholine; FA, fatty acid; GSH, reduced glutathione

Notably, after correction for multiple testing, SSRI-cases exhibited alterations in metabolites related to antioxidant defense such as reduced and oxidized glutathione (GSH and GSSG, respectively), cysteinylglycine, dehydroascorbic acid (DHA), and biliverdin (Figure 2). Furthermore, SSRI-cases exhibited increased levels of serylleucine, citric acid, and monoacylglycerides (1-monostearin, 1-monopalmitin) and decreased levels of nicotinamide adenine dinucleotide (NADH), and phosphocreatine, as well as metabolites possibly linked to external exposure, epigallocatechin and myristamine oxide. However, the 11 metabolites with biological relevance were chosen for further investigation via linear regression analysis, where the impact of SSRI usage remained significant for all metabolites (Supplementary Table 4). Moreover, biliverdin and cysteinylglycine levels were influenced by the mode of delivery, and GSH and cysteinylglycine levels were impacted by preeclampsia.



Figure 2 The identified and significantly altered metabolites with biological relevance. Group means and standard deviations are shown. All shown results remained significant when confounding lifestyle and pregnancy related variables were considered (Supplementary Table 3). GSSG, oxidized glutathione; GSH, reduced glutathione; DHA, dehydroascorbic acid; NADH, nicotinamide adenine dinucleotide; q, FDR corrected p-value; d, Cohen's d effect size; VIP, Variable Importance in Projection value from partial least sum of squares discriminant analysis

Molecular features with p-value < 0.05 and q-value > 0.05 were considered as trends. Increasing trends among SSRI-cases were observed e.g., in the levels of several leucine dipeptides, as well as adenosine monophosphate, guanosine-5'-monophosphate, 1-methyl adenosine, and gamma-glutamyl-cysteine, whereas decreasing trends were observed among SSRI-cases e.g., in the levels of several phosphatidylcholines, adenosine diphosphate, 3-indolepropionic acid, cholesterol 7-ketocholesterol, and N-stearoyl-D-sphingomyelin (Figure 1c, Supplementary table 2).

Metabolites and maternal-neonatal traits

Among the SSRI-cases, the Apgar score at 5 minutes positively correlated with GSH (r = 0.54, p = 0.006), cysteinylglycine (r = 0.56, p = 0.004), citric acid (r = 0.50, p = 0.01), and 1-monostearin (r = 0.43, p = 0.03) (Figure 3). Interestingly, in the control group, the effect was opposite, yet insignificant. We found no associations between placental weight, infant's birth weight and the significant metabolites.



Figure 3 Associations between significantly altered metabolites and Apgar score at 5 minutes among selective serotonin reuptake inhibitor (SSRI) -cases (n = 24) and controls (n = 24). GSH, reduced glutathione

Calculated indicators of placental dysfunction and toxicity

The placental weight and birth weight ratio is used as a marker of placental efficiency and fetal growth [31]. Furthermore, the ratio of GSH to GSSG (GSH:GSSG ratio) is a marker of oxidative stress, increased ratio implicating enhanced antioxidant activity [32]. Therefore, we explored the two ratios in our cohort. Considering the placental weight and birth weight ratio, we found no significant differences between the groups (Table 1). However, SSRI-cases had nearly twofold GSH:GSSG ratio ($M = 10.02$ vs. 5.92, $p < 0.001$, $d = 2.24$) compared to controls and the impact of SSRI usage remained significant after adjusting for confounding lifestyle and pregnancy related variables, reflecting efficient glutathione recycling (Supplementary Table 4).

Discussion

The present study aimed to characterize differences in the placental metabolome between SSRI-treated pregnancies and controls. We detected significant alterations in the metabolite profiles suggesting a response to modified oxidative stress status and energy metabolism within the placenta from the SSRI-treated pregnancies.

In our cohort, SSRI treatment was associated with a decreased level of GSSG ($d = -1.32$), an increased level of GSH ($d = 1.09$), and an increased GSH:GSSG ratio ($d = 2.24$). The placenta generates both pro-oxidant agents such as reactive oxygen species (ROS) and antioxidants, maintaining a robust antioxidant defense system [33]. However, intrinsic and environmental factors can disrupt this redox balance, leading to oxidative stress. Placental oxidative stress is linked to pregnancy complications such as GDM, preeclampsia, and intrauterine growth restriction (IUGR), characterized by trophoblast apoptosis and deportation, and changes in placental vascular reactivity, as reviewed in [34]. Along with other mechanisms, glutathione works as the principal non-enzymatic defense mechanism against accumulation of ROS [35]. In the case of oxidative insult, GSH is oxidized to GSSG leading to reduced cellular GSH levels and neutralization of free radicals or ROS (Figure 4) [36]. Consequently, GSSG is reduced back to GSH.



Figure 4 Metabolic pathways related to antioxidative defense. Reduced glutathione (GSH) is oxidized leading to reduced cellular GSH levels and neutralization of reactive oxygen species (ROS). Consequently, oxidized glutathione (GSSG) is reduced back to GSH. Ascorbic acid (AA) oxidizes to dehydroascorbic acid (DHA) which can reduce back to AA using GSH as the reductant. Under oxidative stress, AA scavenges ROS, while DHA enhances glutathione synthesis. Furthermore, oxidative stress induces the formation of biliverdin, which is rapidly reduced to bilirubin. Furthermore, bilirubin can be recycled back to biliverdin. The upward (↑) and downward (↓) arrows represent the observed effect in SSRI-cases compared to controls, whereas the curved arrows represent the direction of the metabolic reaction. Created in BioRender

Our findings on glutathione metabolism align with those of Ferreira et al. (2020), who reported that improved antioxidant defense in preeclamptic placentas is linked to a protective mechanism against oxidative stress [37]. Furthermore, elevated placental GSH was positively associated with perinatal outcomes in preeclamptic pregnancies, consistent with our observation of a positive correlation between GSH levels and Apgar scores at 5 minutes [37]. In our cohort, there were a total of three preeclampsia cases among the groups and preeclampsia impacted the association between SSRI usage and GSH. However, the small sample size of preeclamptic placentas raises questions about the validity of the effect. Moreover, SSRI-cases exhibited an increased level of cysteinylglycine ($d = 1.10$), a breakdown product of glutathione, along with an increasing trend in gamma-glutamyl-cysteine ($p < 0.05$, $q > 0.05$), a precursor to glutathione. These findings suggest alterations in the glutathione metabolism pathway.

Interestingly, ascorbic acid and glutathione share a metabolic pathway (Figure 4). Under oxidative stress, GSH regenerates ascorbic acid by reducing DHA, while DHA enhances glutathione synthesis [38,39]. This mutual regulation ensures the synthesis of both compounds. In addition to a decreased

placental DHA level in SSRI-cases (d = -1.23), an upward trend in ascorbic acid levels ($p < 0.05$, $q > 0.05$), was observed, suggesting increased ascorbic acid synthesis accompanied by enhanced glutathione synthesis. Ascorbic acid is the most abundant water-soluble antioxidant present within cells and extracellular fluids, and it oxidizes to DHA, which can revert to ascorbic acid [39]. Ascorbic acid has been studied more extensively than DHA in placental metabolism. In normal full-term pregnancies, circulating maternal ascorbic acid levels have been linked to apoptosis and antioxidant status of trophoblasts, without affecting placental or newborn weight. [40]. Decreased circulating ascorbic acid levels have been observed in patients with preeclampsia [41], but ascorbic acid supplementation has not been proven effective in preventing the condition as reviewed in meta-analyses and systematic reviews [42–44]. However, to our knowledge, this is the first study measuring placental ascorbic acid or DHA levels.

Oxidative stress has been linked to pathogenesis of depression [45,46]. On the contrary, SSRIs alleviate oxidative stress in unipolar and antenatal depressive patients [47–49] and reverse the reduction in circulating ascorbic acid levels caused by depression in non-pregnant individuals [49]. Indeed, SSRIs impact redox homeostasis, possessing both pro- and antioxidant effects depending on the redox state, tissue, and dose, as reviewed in [50]. In meta-analysis of observational studies, SSRIs were suggested to serve as antioxidants [51] and serotonin itself possesses antioxidant effects in vitro [52]. Jorgensen et al. (2022) proposed that inhibiting SERT raises extracellular serotonin in the periphery or central nervous system potentially reducing intracellular oxidative stress by altering mitochondrial function via 5-HT_{2A} activation [48]. In rodents, SSRIs appear to alleviate oxidative changes in the presence of pre-existing oxidative insult by targeting both enzymatic and non-enzymatic defense mechanisms, such as increasing GSH levels [50]. Moreover, rodent studies indicate that SSRIs may have diverse effects on the antioxidant enzyme glutathione-S-transferase (GST), ranging from activation to inhibition, or showing no significant impact [50], whereas studies in human placental GST enzyme suggest an inhibitory effect of a specific SSRI, fluoxetine [15]. In our previous study using the same cohort, after adjusting for confounding factors, SSRIs had an increasing, yet insignificant effect on GST activity in placentas exposed to SSRIs [11].

Furthermore, the abundance level of biliverdin, a product of heme metabolism, was decreased in SSRI-cases (d = -0.93), whereas we observed no differences in bilirubin levels between groups. Biliverdin is rapidly reduced to bilirubin under physiological conditions [53,54]. Both biliverdin and bilirubin are potent antioxidants [55]. Oxidative stress activates heme oxygenase 1 (HO-1), which converts heme to biliverdin [56]. Interestingly, in the presence of ROS, bilirubin can be recycled back to biliverdin, thus reducing bilirubin levels, and increasing biliverdin levels (Figure 4) [57]. Bilirubin produced by the fetal liver is excreted into maternal circulation via the placenta, since in large

quantities, bilirubin can cause fetal hyperbilirubinemia [58]. Earlier studies indicate that bilirubin, but not biliverdin, undergoes bidirectional transplacental transfer [59]. We could not determine whether the biliverdin is of maternal or fetal origin. It is possible that biliverdin was reduced to bilirubin and then excreted into maternal circulation, balancing bilirubin levels between groups. The relationship between biliverdin/bilirubin and SSRIs has not been previously studied.

In SSRI-cases, increased levels of the monoacylglycerides 1-monostearin ($d = 1.57$) and 1-monopalmitin ($d = 1.60$) were strongly associated with SSRI usage. These transient lipids are part of the glycerolipid/free fatty acid cycle, which is active in all cells and produces various lipid-signaling molecules and growth signals [60]. This cycle is involved in processes such as cell growth, apoptosis, insulin metabolism, heat production, and energy expenditure. The existing literature on the biological relevance of these metabolites is scarce, despite observed associations with symptom reduction after a placebo treatment in non-pregnant patients with major depressive disorder [61] and with type 2 diabetes mellitus [62]. In our cohort, GDM status was not linked to these metabolites, but since SSRIs are potential inducers of insulin resistance [63], the significance of monoacylglycerides for placental metabolism requires further study.

Phosphocreatine, the phosphorylated form of the amino acid creatine, plays a crucial role in maintaining ATP availability [64]. Ellery et al. (2017) suggested that creatine metabolism might influence placental bioenergetics and fetal development [65]. Moreover, studies indicate that a hypoxic placenta may rely more on creatine and the creatine kinase system to stabilize ATP levels, manifesting as increased system function, as reviewed in [66]. Our findings of decreased phosphocreatine in SSRI-cases ($d = -0.93$) may suggest reduced local creatine synthesis, yet the implications remain unclear.

We observed increased levels of the dipeptide serylleucine ($d = 0.98$) and trends of increase in other leucine dipeptides ($p < 0.05$, $q > 0.05$), in SSRI-cases. Earlier studies have shown that amino acids can be absorbed in the placenta as dipeptides and then hydrolyzed into their component amino acids [67]. The developing fetus relies heavily on maternal amino acid supply for protein synthesis and other metabolic processes [68]. Changes in placental amino acid transport could affect fetal growth, with enhanced transport linked to fetal overgrowth [68]. Amino acids are absorbed from maternal circulation since neither the placenta, nor the fetus can synthesize them [68].

Interestingly, the alterations were specific to leucine dipeptides, as no changes were observed in the component amino acids. Decreased circulating leucine levels have been associated with depression [69,70], while pharmacological treatment appears to reverse leucine downregulation in animal

models of depression [71]. More research is needed to understand these results since there are no previous reports on placental leucine or leucine dipeptides.

Overall, the alterations in glutathione, biliverdin and ascorbic acid metabolism indicate enhancement of the antioxidative defense system. Oxidative stress modifies cellular proteins, reflecting changes in enzyme activities and normal cell functions [72]. Moreover, mitochondrial ROS disrupt most cellular metabolic processes, such as the citric acid cycle, urea cycle, amino acid metabolism, heme synthesis, and fatty acid oxidation [73]. Dysregulated placental oxidant-antioxidant balance compromises the proper development of fetoplacental unit and therefore the fetus [40].

Speculatively, SSRIs could alleviate placental oxidative changes caused by depression or other mental health disorders, aligning with previous studies that focus on circulating oxidative stress and antioxidant markers. Conversely, the observed changes could contribute to pregnancy complications or influence fetal programming, leading to long-term effects on the fetus. Thus, the molecular mechanisms need to be fully elucidated. Furthermore, the clinical significance of observed alterations related to energy metabolism require further investigation. Notably, in addition to GSH and cysteinylglycine, citric acid and 1-monostearin, showed a positive correlation with the 5-minute Apgar score in SSRI-cases, suggesting that higher levels of these metabolites may be associated with better birth outcomes.

The placental homeostasis of antioxidants, amino acids, and lipids is crucial for optimal fetal development and pregnancy outcomes [74,75]. These components play significant roles in mitigating oxidative stress, ensuring nutrient supply, and regulating fetal growth. Thus, impairments of these processes may lead to adverse pregnancy outcomes and long-term health issues for the child.

A strength of the current study is the possibility of assaying metabolites directly in placental tissue since commonly in clinical studies determination of circulatory or urinary levels is possible due to ethical limitations. According to the clinical records, the cases consistently used SSRIs throughout their pregnancy, minimizing the risk of errors due to medication discontinuation.

Our study has potential limitations. Although the largest to date, the study sample is relatively small. Other limitations include the inability to distinguish the effects of SSRIs from those of mental health disorders, as well as to measure the treatment response to SSRIs. Furthermore, metabolite annotation remains as a major limitation in metabolomics studies, particularly in less studied organs such as the placenta. Given the limited research on placental metabolomics, we believe the findings of this exploratory study are significant. However, the validation of the findings, targeted analysis of selected metabolites such as GSH and GSSG remains to be a subject of future studies.

In conclusion, the study provides crucial and highly valuable new insights into SSRI-induced alterations in the placenta. The findings suggest a complex metabolic shift, potentially indicating a response to changes in redox homeostasis and energy metabolism. Furthermore, specific metabolites could potentially reflect birth outcomes. Since the placenta is a metabolically active organ and fetal development heavily depends on its proper function, further studies are needed to elucidate the clinical significance of the observed effects.

Acknowledgements

This paper belongs to the studies carried out by the Kuopio Birth Cohort consortium (www. KuBiCo.fi) and we thank our colleagues who are responsible for the design and conduct of the KuBiCo. We thank Satu Marttila, Sanna Koivisto, Miia Reponen, and Juulia Kuparinen for expert laboratory assistance, and the staff of the Department of Obstetrics and Gynecology in Kuopio University Hospital. The authors also want to thank the Biocenter Finland and the Biocenter Kuopio for supporting the core LC-MS laboratory facility. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825762.

Declarations of interests

O.K. is the co-founder of Afekta Technologies Ltd., a company that provides metabolomics analysis services (not used here). A.I., M.L., H.S., L.K-N., and J.R report no competing interests.

CRediT Authorship contribution statement

Anna Itkonen: Conceptualization, Formal analysis, Visualization, Data curation, Writing – original draft, Writing – review & editing, **Olli Kärkkäinen:** Conceptualization, Methodology, Formal analysis, Writing – review & editing, **Marko Lehtonen:** Methodology, Investigation, Writing – review & editing: **Heidi Sahlman:** Conceptualization, Resources, Data curation, Supervision, Writing – review & editing, **Leea Keski-Nisula:** Resources, Data curation, Writing – review & editing, **Jaana Rysä:** Conceptualization, Resources, Supervision, Project administration, Funding acquisition, Writing – review & editing.

Funding

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825762

Ethics approval

All participants in the KuBiCo study provided a written informed consent. The study was conducted in accordance with the guidelines outlined in the Declaration of Helsinki. Ethical approval was obtained from the Research Ethics Committee of the Hospital District of Central Finland in Jyväskylä, Finland on November 15, 2011 (18U/2011). The study was conducted in accordance with the Strengthening the reporting of observational studies in epidemiology (STROBE) guidelines.

Data Availability

All the data necessary to evaluate the conclusions is included in the paper and the Supporting Information. The authors are willing to provide additional data related to this paper upon reasonable request.

References

[1] S.I. Lusskin, S.J. Khan, C. Ernst, S. Habib, M.E. Fersh, E.S. Albertini, Pharmacotherapy for Perinatal Depression, Clin Obstet Gynecol 61 (2018) 544–561. https://doi.org/10.1097/GRF.0000000000000365.

[2] P. Kratimenos, A.A. Penn, Placental programming of neuropsychiatric disease, Pediatric Research 2019 86:2 86 (2019) 157–164. https://doi.org/10.1038/s41390-019-0405-9.

[3] H. Horackova, R. Karahoda, L. Cerveny, V. Vachalova, R. Ebner, C. Abad, F. Staud, Effect of selected antidepressants on placental homeostasis of serotonin: Maternal and fetal perspectives, Pharmaceutics 13 (2021) 1306. https://doi.org/10.3390/PHARMACEUTICS13081306/S1.

[4] D.F. Balkovetz, C. Tiruppathi, F.H. Leibach, V.B. Mahesh, V. Ganapathy, Evidence for an imipramine-sensitive serotonin transporter in human placental brush-border membrane, Journal of Biological Chemistry 264 (1989) 2195–2198. https://doi.org/10.1016/s0021-9258(18)94161-x.

[5] M. Perić, I. Bečeheli, L. Čičin-Šain, G. Desoye, J. Štefulj, Serotonin system in the human placenta – the knowns and unknowns, Front Endocrinol 13 (2022). https://doi.org/10.3389/FENDO.2022.1061317/FULL.

[6] C.S. Rosenfeld, Placental serotonin signaling, pregnancy outcomes, and regulation of fetal brain development, Biol Reprod 102 (2020) 532–538. https://doi.org/10.1093/biolre/ioz204.

[7] F. Cô, C. Cile Fligny, E. Bayard, J.-M. Launay, M.D. Gershon, J. Mallet, G. Vodjdani, Maternal serotonin is crucial for murine embryonic development, (2006). https://doi.org/10.1073/pnas.0606722104

[8] P. Desaunay, M. Eslier, J. Alexandre, M. Dreyfus, B. Chrétien, F. Guénolé, Antidepressants and fetal death: A systematic review and disproportionality analysis in the WHO safety database (VigiBase®), Psychiatry Res 339 (2024) 116048. https://doi.org/10.1016/J.PSYCHRES.2024.116048.

[9] J.D.A. Olivier, H. Åkerud, A. Skalkidou, H. Kaihola, I. Sundström-Poromaa, The effects of antenatal depression and antidepressant treatment on placental gene expression, Front Cell Neurosci 8 (2015) 1–17. https://doi.org/10.3389/FNCEL.2014.00465.

[10] H. Kaihola, J. Olivier, I.S. Poromaa, H. Åkerud, The Effect of Antenatal Depression and Selective Serotonin Reuptake Inhibitor Treatment on Nerve Growth Factor Signaling in Human Placenta, PLoS One 10 (2015) e0116459. https://doi.org/10.1371/JOURNAL.PONE.0116459.

[11] H. Sahlman, A. Itkonen, M. Lehtonen, L. Keski-Nisula, J. Rysä, Altered activities of CYP1A1 and CYP19A1 enzymes in women using SSRI medication during pregnancy, Placenta 129 (2022) 30–35. https://doi.org/10.1016/J.PLACENTA.2022.09.013.

[12] M. Bhuiyan, S. Petropoulos, W. Gibb, S.G. Matthews, Sertraline alters multidrug resistance phosphoglycoprotein activity in the mouse placenta and fetal blood-brain barrier, Reproductive Sciences 19 (2012) 407–415. https://doi.org/10.1177/1933719111424438.

[13] N. Arumugasaamy, A. Gudelsky, A. Hurley-Novatny, P.C.W. Kim, J.P. Fisher, Model Placental Barrier Phenotypic Response to Fluoxetine and Sertraline: A Comparative Study, Adv Healthc Mater 8 (2019) 1900476. https://doi.org/10.1002/ADHM.201900476.

[14] A.-A. Hudon Thibeault, Y. López de los Santos, N. Doucet, J.T. Sanderson, C. Vaillancourt, Serotonin and serotonin reuptake inhibitors alter placental aromatase, J Steroid Biochem Mol Biol 195 (2019) 105470. https://doi.org/10.1016/j.jsbmb.2019.105470.

[15] O. Dalmizrak, G. Kulaksiz-Erkmen, N. Ozer, Fluoxetine-induced toxicity results in human placental glutathione S-transferase-π (GST-π) dysfunction, *Drug Chem Toxicol*. 2016;39(4):439-444. DOI: 10.3109/01480545.2016.1141422

[16] Å. Edvinsson, C. Hellgren, T. Kunovac Kallak, H. Åkerud, A. Skalkidou, E. Stener-Victorin, R. Fornes, O. Spigset, S. Lager, J. Olivier, I. Sundström-Poromaa, The effect of antenatal depression and antidepressant treatment on placental tissue: A protein-validated gene expression study, BMC Pregnancy Childbirth 19 (2019) 1–13. https://doi.org/10.1186/S12884-019-2586-Y

[17] M. Beyazyüz, Y. Albayrak, O.B. Eğilmez, N. Albayrak, E. Beyazyüz, Relationship between SSRIs and metabolic syndrome abnormalities in patients with generalized anxiety disorder: A prospective study, Psychiatry Investig 10 (2013) 148–154. https://doi.org/10.4306/pi.2013.10.2.148.

[18] S. Bhattacharyya, A.T. Ahmed, M. Arnold, D. Liu, C. Luo, H. Zhu, S. Mahmoudiandehkordi, D. Neavin, G. Louie, B.W. Dunlop, M.A. Frye, L. Wang, R.M. Weinshilboum, R.R. Krishnan, A.J. Rush, R. Kaddurah-Daouk, Metabolomic signature of exposure and response to

citalopram/escitalopram in depressed outpatients, Transl Psychiatry 9 (2019). https://doi.org/10.1038/s41398-019-0507-5.

[19] M.M. Ulaszewska, C.H. Weinert, A. Trimigno, R. Portmann, C. Andres Lacueva, R. Badertscher, L. Brennan, C. Brunius, A. Bub, F. Capozzi, M. Cialiè Rosso, C.E. Cordero, H. Daniel, S. Durand, B. Egert, P.G. Ferrario, E.J.M. Feskens, P. Franceschi, M. Garcia-Aloy, F. Giacomoni, P. Giesbertz, R. González-Domínguez, K. Hanhineva, L.Y. Hemeryck, J. Kopka, S.E. Kulling, R. Llorach, C. Manach, F. Mattivi, C. Migné, L.H. Münger, B. Ott, G. Picone, G. Pimentel, E. Pujos-Guillot, S. Riccadonna, M.J. Rist, C. Rombouts, J. Rubert, T. Skurk, P.S.C. Sri Harsha, L. Van Meulebroek, L. Vanhaecke, R. Vázquez-Fresno, D. Wishart, G. Vergères, Nutrimetabolomics: An Integrative Action for Metabolomic Analyses in Human Nutritional Studies, Mol Nutr Food Res 63 (2019) 1800384. https://doi.org/10.1002/MNFR.201800384.

[20] S. Ramirez-Hincapie, B. Birk, P. Ternes, V. Giri, V. Haake, M. Herold, F.M. Zickgraf, A. Verlohner, H.A. Huener, H. Kamp, P. Driemert, R. Landsiedel, E. Richling, D. Funk-Weyer, B. van Ravenzwaay, A high-throughput metabolomics in vitro platform for the characterization of hepatotoxicity, Cell Biol Toxicol 39 (2023) 2899–2917. https://doi.org/10.1007/S10565-023-09809-6.

[21] P. Huuskonen, L. Keski-Nisula, S. Heinonen, S. Voutilainen, T.-P. Tuomainen, J. Pekkanen, J. Lampi, S.M. Lehto, H. Haaparanta, A.-P. Elomaa, R. Voutilainen, K. Backman, H. Kokki, K. Kumpulainen, J. Paananen, K. Vähäkangas, M. Pasanen, Kuopio birth cohort – design of a Finnish joint research effort for identification of environmental and lifestyle risk factors for the wellbeing of the mother and the newborn child, BMC Pregnancy Childbirth 18 (2018) 381. https://doi.org/10.1186/s12884-018-2013-9.

[22] E. von Elm, D.G. Altman, M. Egger, S.J. Pocock, P.C. Gøtzsche, J.P. Vandenbroucke, The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies., Lancet 370 (2007) 1453–1457. https://doi.org/10.1016/S0140-6736(07)61602-X.

[23] H.A.K. Lapatto, M. Kuusela, A. Heikkinen, M. Muniandy, B.W. van der Kolk, S. Gopalakrishnan, N. Pöllänen, M. Sandvik, M.S. Schmidt, S. Heinonen, S. Saari, J. Kuula, A. Hakkarainen, J. Tampio, T. Saarinen, M.R. Taskinen, N. Lundbom, P.H. Groop, M. Tiirola, P. Katajisto, M. Lehtonen, C. Brenner, J. Kaprio, S. Pekkala, M. Ollikainen, K.H. Pietiläinen, E. Pirinen, Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study, Sci Adv 9 (2023). https://doi.org/10.1126/SCIADV.ADD5163

[24] H. Tsugawa, T. Cajka, T. Kind, Y. Ma, B. Higgins, K. Ikeda, M. Kanazawa, J. Vandergheynst, O. Fiehn, M. Arita, MS-DIAL: data-independent MS/MS deconvolution for comprehensive metabolome analysis, Nature Methods 2015 12:6 12 (2015) 523–526. https://doi.org/10.1038/nmeth.3393.

[25] A. Klåvus, M. Kokla, S. Noerman, V.M. Koistinen, M. Tuomainen, I. Zarei, T. Meuronen, M.R. Häkkinen, S. Rummukainen, A.F. Babu, T. Sallinen, O. Kärkkäinen, J. Paananen, D. Broadhurst, C. Brunius, K. Hanhineva, "notame": Workflow for Non-Targeted LC-MS Metabolic Profiling, Metabolites 10 (2020). https://doi.org/10.3390/METABO10040135.

[26] T. Jääskeläinen, O. Kärkkäinen, J. Jokkala, K. Litonius, S. Heinonen, S. Auriola, M. Lehtonen, K. Hanhineva, H. Laivuori, E. Kajantie, J. Kere, K. Kivinen, A. Pouta, A Non-Targeted LC-MS Profiling Reveals Elevated Levels of Carnitine Precursors and Trimethylated Compounds in the Cord Plasma of Pre-Eclamptic Infants, Sci Rep 8 (2018). https://doi.org/10.1038/S41598-018-32804-5.

[27] T. Jääskeläinen, O. Kärkkäinen, J. Jokkala, A. Klåvus, S. Heinonen, S. Auriola, M. Lehtonen, K. Hanhineva, H. Laivuori, E. Kajantie, J. Kere, K. Kivinen, A. Pouta, A non-targeted LC–MS metabolic profiling of pregnancy: longitudinal evidence from healthy and pre-eclamptic pregnancies, Metabolomics 17 (2021) 1–12. https://doi.org/10.1007/S11306-020-01752-5.

[28] T. Mansell, A. Vlahos, F. Collier, A.L. Ponsonby, P. Vuillermin, S. Ellul, M.L.K. Tang, D. Burgner, R. Saffery, The newborn metabolome: associations with gestational diabetes, sex, gestation, birth mode, and birth weight, Pediatric Research 2021 91:7 91 (2021) 1864–1873. https://doi.org/10.1038/s41390-021-01672-7.

[29] S. Masalin, A. Klåvus, K. Rönö, H.A. Koistinen, V. Koistinen, O. Kärkkäinen, T.J. Jääskeläinen, M.M. Klemetti, Analysis of early-pregnancy metabolome in early- and late-onset gestational diabetes reveals distinct associations with maternal overweight, Diabetologia (2024). https://doi.org/10.1007/S00125-024-06237-X.

[30] L.W. Sumner, A.E. Alexander, A. Ae, D.B. Ae, M.H.B. Ae, R. Beger, C.A. Daykin, A.E. Teresa, W.-M. Fan, A.E. Oliver, F. Ae, R. Goodacre, A.E. Julian, L. Griffin, A.E. Thomas, H. Ae, N. Hardy, A.E. James, H. Ae, R. Higashi, A.E. Joachim, K. Ae, A.N.L. Ae, J.C. Lindon, A.E. Philip, M. Ae, A.W.N. Ae, M.D. Reily, J.J.T. Ae, M.R. Viant, L.W. Sumner, A. Amberg, D. Barrett, M.H. Beale, R. Beger, C.A. Daykin, Á.R. Higashi, R. Higashi, O. Fiehn, R. Goodacre, Proposed minimum reporting standards for chemical analysis, Metabolomics 2007 3:3 3 (2007) 211–221. https://doi.org/10.1007/S11306-007-0082-2.

[31] T. Burkhardt, L. Schäffer, C. Schneider, R. Zimmermann, J. Kurmanavicius, Reference values for the weight of freshly delivered term placentas and for placental weight–birth weight ratios, European Journal of Obstetrics & Gynecology and Reproductive Biology 128 (2006) 248–252. https://doi.org/10.1016/J.EJOGRB.2005.10.032.

[32] D.M. Townsend, K.D. Tew, H. Tapiero, The importance of glutathione in human disease, Biomedicine & Pharmacotherapy 57 (2003) 145–155. https://doi.org/10.1016/S0753-3322(03)00043-X.

[33] V. Toescu, S.L. Nuttall, U. Martin, M.J. Kendall, F. Dunne, Oxidative stress and normal pregnancy, Clin Endocrinol (Oxf) 57 (2002) 609–613. https://doi.org/10.1046/J.1365-2265.2002.01638.X.

[34] L. Myatt, X. Cui, Oxidative stress in the placenta, Histochem Cell Biol 122 (2004) 369–382. https://doi.org/10.1007/S00418-004-0677-X.

[35] R. Kohen, A. Nyska, Invited Review: Oxidation of Biological Systems: Oxidative Stress Phenomena, Antioxidants, Redox Reactions, and Methods for Their Quantification, Http://Dx.Doi.Org/10.1080/01926230290166724 30 (2002) 620–650. https://doi.org/10.1080/01926230290166724.

[36] G. Wu, Y.Z. Fang, S. Yang, J.R. Lupton, N.D. Turner, Glutathione Metabolism and Its Implications for Health, J Nutr 134 (2004) 489–492. https://doi.org/10.1093/JN/134.3.489.

[37] R.C. Ferreira, M.B.T. Fragoso, M.C. dos S. Tenório, A.S. da P. Martins, A.U. Borbely, F.A. Moura, M.O.F. Goulart, A.C.M. de Oliveira, Biomarkers of placental redox imbalance in pregnancies with preeclampsia and consequent perinatal outcomes, Arch Biochem Biophys 691 (2020) 108464. https://doi.org/10.1016/J.ABB.2020.108464.

[38] G. Bánhegyi, L. Braun, M. Csala, F. Puskás, J. Mandl, Ascorbate Metabolism and Its Regulation in Animals, Free Radic Biol Med 23 (1997) 793–803. https://doi.org/10.1016/S0891-5849(97)00062-2.

[39] J.X. Wilson, The physiological role of dehydroascorbic acid, FEBS Lett 527 (2002) 5–9. https://doi.org/10.1016/S0014-5793(02)03167-8.

[40] Y.M. Ahn, Y.J. Kim, H. Park, B. Park, H. Lee, Prenatal Vitamin C Status is Associated with Placental Apoptosis in Normal-term Human Pregnancies, Placenta 28 (2007) 31–38. https://doi.org/10.1016/J.PLACENTA.2006.01.018.

[41] M.S. Mikhail, A. Anyaegbunam, D. Garfinkel, P.R. Palan, J. Basu, S.L. Romney, Preeclampsia and antioxidant nutrients: Decreased plasma levels of reduced ascorbic acid, α-tocopherol, and beta-carotene in women with preeclampsia, Am J Obstet Gynecol 171 (1994) 150–157. https://doi.org/10.1016/0002-9378(94)90462-6.

[42] A.M.R. Salles, T.F. Galvao, M.T. Silva, L.C.D. Motta, M.G. Pereira, Antioxidants for Preventing Preeclampsia: A Systematic Review, The Scientific World Journal 2012 (2012) 243476. https://doi.org/10.1100/2012/243476.

[43] A.C. Rossi, P.M. Mullin, Prevention of pre-eclampsia with low-dose aspirin or vitamins C and E in women at high or low risk: a systematic review with meta-analysis, European Journal of Obstetrics & Gynecology and Reproductive Biology 158 (2011) 9–16. https://doi.org/10.1016/J.EJOGRB.2011.04.010.

[44] C.H. Christiansen, S. Høgh, L. Rode, J.B. Schroll, H.K. Hegaard, H.T. Wolf, Multivitamin use and risk of preeclampsia: A systematic review and meta-analysis, Acta Obstet Gynecol Scand 101 (2022) 1038–1047. https://doi.org/10.1111/AOGS.14356.

[45] P. Palta, L.J. Samuel, E.R. Miller, S.L. Szanton, Depression and oxidative stress: results from a meta-analysis of observational studies, Psychosom Med 76 (2014) 12–19. https://doi.org/10.1097/PSY.0000000000000009.

[46] P. Czarny, P. Wigner, P. Galecki, T. Sliwinski, The interplay between inflammation, oxidative stress, DNA damage, DNA repair and mitochondrial dysfunction in depression, Prog Neuropsychopharmacol Biol Psychiatry 80 (2018) 309–321. https://doi.org/10.1016/J.PNPBP.2017.06.036.

[47] K.K. Venkatesh, J.D. Meeker, D.E. Cantonwine, T.F. McElrath, K.K. Ferguson, Association of antenatal depression with oxidative stress and impact on spontaneous preterm birth, Journal of Perinatology 2019 39:4 39 (2019) 554–562. https://doi.org/10.1038/s41372-019-0317-x.

[48] A. Jorgensen, K. Köhler-Forsberg, T. Henriksen, A. Weimann, I. Brandslund, C. Ellervik, H.E. Poulsen, G.M. Knudsen, V.G. Frokjaer, M.B. Jorgensen, Systemic DNA and RNA damage from oxidation after serotonergic treatment of unipolar depression, Translational Psychiatry 2022 12:1 12 (2022) 1–8. https://doi.org/10.1038/s41398-022-01969-z.

[49] S.D. Khanzode, G.N. Dakhale, S.S. Khanzode, A. Saoji, R. Palasodkar, Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors, Redox Report 8 (2003) 365–370. https://doi.org/10.1179/135100003225003393.

[50] M.G. Ștefan, B. Kiss, A.C. Gutleb, F. Loghin, Redox metabolism modulation as a mechanism in SSRI toxicity and pharmacological effects, Archives of Toxicology 2020 94:5 94 (2020) 1417–1441. https://doi.org/10.1007/S00204-020-02721-6.

[51] S. Jimenez-Fernandez, M. Gurpegui, F. Diaz-Atienza, L. Perez-Costillas, M. Gerstenberg, C.U. Correll, Oxidative Stress and Antioxidant Parameters in Patients With Major Depressive Disorder Compared to Healthy Controls Before and After Antidepressant Treatment: Results From a Meta-Analysis, J Clin Psychiatry 76 (2015) 13705. https://doi.org/10.4088/JCP.14R09179.

[52] S. Azouzi, H. Santuz, S. Morandat, C. Pereira, F. Côté, O. Hermine, K. El Kirat, Y. Colin, C. Le Van Kim, C. Etchebest, P. Amireault, Antioxidant and Membrane Binding Properties of Serotonin Protect Lipids from Oxidation, Biophys J 112 (2017) 1863–1873. https://doi.org/10.1016/J.BPJ.2017.03.037.

[53] N.G. Abraham, A. Kappas, Pharmacological and Clinical Aspects of Heme Oxygenase, Pharmacol Rev 60 (2008) 79–127. https://doi.org/10.1124/PR.107.07104.

[54] R. Tenhunen, H.S. Marver, R. Schmid, The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase., Proc Natl Acad Sci U S A 61 (1968) 748–755. https://doi.org/10.1073/PNAS.61.2.748.

[55] C. Mancuso, Biliverdin as a disease-modifying agent: An integrated viewpoint, Free Radic Biol Med 207 (2023) 133–143. https://doi.org/10.1016/J.FREERADBIOMED.2023.07.015.

[56] M.D. Maines, New insights into biliverdin reductase functions: Linking heme metabolism to cell signaling, Physiology 20 (2005) 382–389. https://doi.org/10.1152/PHYSIOL.00029.2005.

[57] D.E. Barañano, M. Rao, C.D. Ferris, S.H. Snyder, Biliverdin reductase: A major physiologic cytoprotectant, Proceedings of the National Academy of Sciences 99 (2002) 16093–16098. https://doi.org/10.1073/PNAS.252626999.

[58] R.I.R. Macias, J.J.G. Marin, M.A. Serrano, Excretion of biliary compounds during intrauterine life, World Journal of Gastroenterology: WJG 15 (2009) 817. https://doi.org/10.3748/WJG.15.817.

[59] A.F. McDonagh, L.A. Palma, R. Schmid, Reduction of biliverdin and placental transfer of bilirubin and biliverdin in the pregnant guinea pig, Biochemical Journal 194 (1981) 273–282. https://doi.org/10.1042/BJ1940273.

[60] M. Prentki, S.R.M. Madiraju, Glycerolipid Metabolism and Signaling in Health and Disease, Endocr Rev 29 (2008) 647–676. https://doi.org/10.1210/ER.2008-0007.

[61] R. Kaddurah-Daouk, S.H. Boyle, W. Matson, S. Sharma, S. Matson, H. Zhu, M.B. Bogdanov, E. Churchill, R.R. Krishnan, A.J. Rush, E. Pickering, M. Delnomdedieu, Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept, Translational Psychiatry 2011 1:7 1 (2011) e26–e26. https://doi.org/10.1038/tp.2011.22.

[62] M. Zeng, Z. Che, Y. Liang, B. Wang, X. Chen, H. Li, J. Deng, Z. Zhou, GC-MS based plasma metabolic profiling of type 2 diabetes mellitus, Chromatographia 69 (2009) 941–948. https://doi.org/10.1365/S10337-009-1040-0.

[63] R. Isaac, S. Boura-Halfon, D. Gurevitch, A. Shainskaya, Y. Levkovitz, Y. Zick, Selective Serotonin Reuptake Inhibitors (SSRIs) Inhibit Insulin Secretion and Action in Pancreatic β Cells, J Biol Chem 288 (2012) 5682. https://doi.org/10.1074/JBC.M112.408641.

[64] W.R. Ellington, Phosphocreatine Represents a Thermodynamic and Functional Improvement Over Other Muscle Phosphagens, Journal of Experimental Biology 143 (1989) 177–194. https://doi.org/10.1242/JEB.143.1.177.

[65] S.J. Ellery, P.A. Della Gatta, C.R. Bruce, G.M. Kowalski, M. Davies-Tuck, J.C. Mockler, P. Murthi, D.W. Walker, R.J. Snow, H. Dickinson, Creatine biosynthesis and transport by the term human placenta, Placenta 52 (2017) 86–93. https://doi.org/10.1016/J.PLACENTA.2017.02.020.

[66] A.M. Muccini, N.T. Tran, D.L. de Guingand, M. Philip, P.A.D. Gatta, R. Galinsky, L.S. Sherman, M.A. Kelleher, K.R. Palmer, M.J. Berry, D.W. Walker, R.J. Snow, S.J. Ellery, Creatine Metabolism in Female Reproduction, Pregnancy and Newborn Health, Nutrients 2021, Vol. 13, Page 490 13 (2021) 490. https://doi.org/10.3390/NU13020490.

[67] S.S. Crandell, E.W. Adcock, F.H. Morriss, Hydrolysis of Dipeptides by Human and Ovine Placentas, Pediatric Research 1981 15:4 15 (1981) 357–361. https://doi.org/10.1203/00006450-198104000-00013.

[68] H. Shimada, T.L. Powell, T. Jansson, Regulation of placental amino acid transport in health and disease, Acta Physiologica 240 (2024) e14157. https://doi.org/10.1111/APHA.14157.

[69] A. Baranyi, O. Amouzadeh-Ghadikolai, D. Von Lewinski, H.B. Rothenhäusler, S. Theokas, C. Robier, H. Mangge, G. Reicht, P. Hlade, A. Meinitzer, Branched-Chain Amino Acids as New Biomarkers of Major Depression - A Novel Neurobiology of Mood Disorder, PLoS One 11 (2016) e0160542. https://doi.org/10.1371/JOURNAL.PONE.0160542.

[70] A.M. Whipp, M. Heinonen-Guzejev, K.H. Pietiläinen, I. van Kamp, J. Kaprio, Branched-chain amino acids linked to depression in young adults, Front Neurosci 16 (2022) 935858. https://doi.org/10.3389/FNINS.2022.935858.

[71] J. Pu, Y. Liu, S. Gui, L. Tian, Y. Yu, D. Wang, X. Zhong, W. Chen, X. Chen, Y. Chen, X. Chen, X. Gong, L. Liu, W. Li, H. Wang, P. Xie, Effects of pharmacological treatment on metabolomic alterations in animal models of depression, Translational Psychiatry 2022 12:1 12 (2022) 1–10. https://doi.org/10.1038/s41398-022-01947-5.

[72] A.M. Pickering, L. Vojtovich, J. Tower, K.J.A. Davies, Oxidative stress adaptation with acute, chronic, and repeated stress, Free Radic Biol Med 55 (2013) 109–118. https://doi.org/10.1016/J.FREERADBIOMED.2012.11.001.

[73] D. Dwivedi, K. Megha, R. Mishra, P.K. Mandal, Glutathione in Brain: Overview of Its Conformations, Functions, Biochemical Characteristics, Quantitation and Potential Therapeutic Role in Brain Disorders, Neurochemical Research 2020 45:7 45 (2020) 1461–1480. https://doi.org/10.1007/S11064-020-03030-1.

[74] A.W. Bell, R.A. Ehrhardt, Regulation of placental nutrient transport and implications for fetal growth, (2002). https://doi.org/10.1079/NRR200239.

[75] M.H. Schoots, S.J. Gordijn, S.A. Scherjon, H. van Goor, J.L. Hillebrands, Oxidative stress in placental pathology, Placenta 69 (2018) 153–161. https://doi.org/10.1016/J.PLACENTA.2018.03.003.